MacroGenics, Inc.

170 articles with MacroGenics, Inc.

• MacroGenics Announces Flotetuzumab Publication in Blood Advances — Role of TP53 abnormalities in immunotherapy response in AML highlighted

  10/15/2020

  MacroGenics, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, announced the publication of a manuscript in Blood Advances, a journal of the American Society of Hematology.

• MacroGenics Announces MGC018 Publication in Molecular Cancer Therapeutics

  9/23/2020

  Phase 1 dose expansion trial evaluating MGC018 in patients with mCRPC, TNBC and NSCLC is currently recruiting patients

• MacroGenics Announces Publication of Flotetuzumab Interim Phase 1/2 Clinical Trial Results in Blood

  9/22/2020

  MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced the publication of a manuscript in Blood , a journal of the American Society of Hematology, which highlights interim results of an ongoing Phase 1/2 clinical trial of flotetuzumab in patients with acute myeloid leukemia (AML). Flotetu

• MacroGenics Announces Development Milestone Achieved in Retifanlimab (MGA012) Collaboration with Incyte

  9/21/2020

  MacroGenics, Inc. (Nasdaq: MGNX), today announced that a $15 million milestone payment has been triggered under its exclusive global collaboration and license agreement with Incyte for retifanlimab (MGA012), an investigational anti-PD-1 monoclonal antibody designed by MacroGenics and licensed to Incyte (as INCMGA00012).

• MacroGenics Announces Presentation of MGD019 Phase 1 Data at the ESMO Virtual Congress 2020

  9/20/2020

  MGD019 well-tolerated with early signals of activity in advanced solid tumors not typically responsive to checkpoint inhibition

• MacroGenics to Participate in Upcoming Investor Conferences - Sep 03, 2020

  9/3/2020

  MacroGenics, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, announced that the Company's management will participate in the following investor conferences in September:

• MacroGenics to Participate in Upcoming Investor Conferences - Aug 05, 2020

  8/5/2020

  MacroGenics, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, announced that the Company's management will participate in the following investor conferences in August:

• MacroGenics Provides Update on Corporate Progress and Second Quarter 2020 Financial ResultsConference call scheduled for today at 4:30 p.m. ET.

  7/30/2020

  MacroGenics, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, provided an update on its corporate progress and reported financial results for the quarter ended June 30, 2020.

• MacroGenics Announces Date of Second Quarter 2020 Financial Results Conference Call

  7/23/2020

  Rockville, MD, July 23, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its financial results for the second quarter 2020 after the market closes on Thursday, July 30, 2020. MacroGenics will host a conference call to discuss the financial results and recent corporate progress on

• MacroGenics Announces Lancet Oncology Publication of Margetuximab Data in Gastric Cancer

  7/9/2020

  MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that Lancet Oncology has published results from a Phase 2 study of margetuximab plus pembrolizumab as a chemotherapy-free regimen for patients with advanced HER2-positive gastroesophageal adenocarcinoma

• MacroGenics Announces Presentation of Preclinical Data at the 2020 AACR Annual Meeting

  6/22/2020

  MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced presentations at the American Association for Cancer Research (AACR) Virtual Annual Meeting II , taking place June 22-24, 2020. “We are pleased to present data at this year’s AACR that highlight three platform technologies upon which

• MacroGenics Appoints Dr. Stephen Eck As Chief Medical Officer

  6/16/2020

  MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced the appointment of Stephen Eck, M.D., Ph.D. as Senior Vice President, Clinical Development & Chief Medical Officer, effective beginning July 1, 2020. “We are excited to announce the addition of Stephen Eck to the MacroGenics leaders

• MacroGenics Announces Margetuximab Granted Orphan Drug Designation in the U.S. for Gastric Cancer

  6/5/2020

  MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to margetuximab, an investigational, Fc-engineered monoclonal antibody targeting HER2 for the treatment of gastric and gastroesophageal junction c

• MacroGenics Announces Publication in Science Translational Medicine Supporting Flotetuzumab Pivotal Study in Patients with Refractory Acute Myeloid Leukemia

  6/3/2020

  MacroGenics, Inc. (NASDAQ: MGNX),today announced research published in the journal Science Translational Medicine that describes a gene expression signature of the tumor microenvironment in patients with acute myeloid leukemia (AML)

• MacroGenics Provides Update on FDA Review of Margetuximab for HER2-Positive Metastatic Breast Cancer

  5/28/2020

  MacroGenics, Inc. announced that during the recent mid-cycle communication with the U.S. Food and Drug Administration, the FDA notified the Company that it is no longer planning to hold an Oncologic Drugs Advisory Committee meeting to discuss the Biologics License Application for margetuximab.

• MacroGenics Announces Registration Study of Flotetuzumab in Patients with Refractory Acute Myeloid Leukemia

  5/27/2020

  MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced plans for a clinical study intended to support registration in the U.S. of flotetuzumab, an investigational, bispecific CD123 x CD3 DART® molecule for patients with acute myeloid leukemia (AML) who are refractory to induction therapy. In

• MacroGenics to Host Conference Call and Webcast to Review Preliminary Clinical Results for MGD013 and MGC018 to be Presented at ASCO

  5/21/2020

  MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced it will host a conference call and audio webcast on Friday, May 29 at 4:30 p.m. ET.

• MacroGenics Announces Preliminary Clinical Results from MGD013 and MGC018 to be Presented at the ASCO Annual Meeting

  5/13/2020

  MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced preliminary results from two of its investigational pipeline molecules.

• MacroGenics Provides Update on Corporate Progress and First Quarter 2020 Financial ResultsConference call scheduled for today at 4:30 p.m. ET.

  5/5/2020

  MacroGenics, Inc. provided an update on its corporate progress and reported financial results for the quarter ended March 31, 2020.

• MacroGenics Announces Presentations at the 2020 ASCO Annual Meeting

  4/29/2020

  MacroGenics, Inc. announced three clinical presentations at the American Society of Clinical Oncology upcoming ASCO20 Virtual Scientific Program to be held May 29-31, 2020.